93 related articles for article (PubMed ID: 17244451)
1. [Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].
Wang ZY; Zhang DZ; Shi XF; Zhou Z; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):13-5. PubMed ID: 17244451
[TBL] [Abstract][Full Text] [Related]
2. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
4. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
5. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
7. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
9. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
10. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
11. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
12. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
[TBL] [Abstract][Full Text] [Related]
14. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
[TBL] [Abstract][Full Text] [Related]
15. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
16. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
[TBL] [Abstract][Full Text] [Related]
17. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
18. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
19. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
Yao GB; Zhu M; Wang YM; Xu DZ; Tan DM; Chen CW; Hou JL
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):891-5. PubMed ID: 17313873
[TBL] [Abstract][Full Text] [Related]
20. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]